logo

Last Update

This profile was last updated on 12/5/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Gary Rabin?

Gary H. Rabin

Chairman and Chief Executive Officer

Ocata Therapeutics, Inc.

HQ Phone:  (508) 756-1212

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Ocata Therapeutics, Inc.

33 Locke Drive

Marlborough, Massachusetts,01752

United States

Company Description

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Ocata's most advanced products are in clinical trials for the treatment of Stargardt's m...more

Background Information

Employment History

Chairman and Chief Executive Officer

Advanced Cell Technology , Inc.


Managing Partner

GR Advisors , LLC


Managing Director, Co-Head and Founder

The Industry Group


Web References(169 Total References)


Milestone in Stem Cell Therapy

www.webrn-maculardegeneration.com [cached]

Gary Rabin, the past chairman and CEO of Ocata Therapeutics, formerly known as Advanced Cell Technology, states that "the end goal for our clinical trials is to test whether or not the retinal pigment epithelial (RPE) cells we make from hESCs are capable of homing to sites of injury in the retina, replacing the native RPE cells that are lost to disease, and ultimately reestablishing the function of this layer of cells in protecting photoreceptors from cell death, i.e. slowing or halting progressive vision loss."


www.bioinformant.com

Nonetheless, on May 1, 2013, the CEO and Chairman of Ocata Therapeutics, Gary Rabin, wrote in a written interview for the Knoepfler Lab Stem Cell Blog that, "Our IP position includes claims around inducing pluripotency using Oct-4, as well as zero footprint reprogramming using vectorless technology.
Interview with Gary Rabin of Advanced Cell Technology (ACT). Knoepfler Lab Stem Cell Blog, [blog]. Available at: http://www.ipscell.com/2013/05/interview-with-gary-rabin-of-advanced-cell-technology-actc/. Web. 9 Apr. 2015. [19] Fate Therapeutics (2012). Fate Therapeutics and BD Biosciences Launch BD SMC4 to Improve Cellular Reprogramming and iPS Cell Culture Applications [Press release]. June 11, 2012.


Resurfacing Damaged Retinas

www.webrn-maculardegeneration.com [cached]

In addition to measuring visual acuity, the clinical sites have been providing us with fundus photographs and other evidence showing that the transplanted RPE cells engrafted in appropriate space and are apparently resurfacing the damaged retinas in our patients," states Gary Rabin, the CEO of Advanced Cell Technology (ACT) in his January 2013 Blog.


Macular Dystrophy and Stem Cells Update

www.webrn-maculardegeneration.com [cached]

However, acccording to Gary Rabin, Advanced Cell Technology's chief executive, "Advanced Cell Technology uses a proprietary technique to extract a single cell from a young embryo, allowing the rest to remain intact and develop normally.


ISPE Boston News Viewing News - Industry News in Brief

www.ispeboston.org [cached]

"We expect that a number of our embryonic stem cell lines will be approved for funding in the coming months," ACT CEO Gary Rabin said in a statement.
ACT has Phase I trials underway for stem cell treatments it has developed for Stargardt's Macular Dystrophy and Dry AMD, which lead to blindness. Rabin wrote in his blog that "myths and misunderstanding" still permeate the stem cell research discussion, though 12 years have passed since the first human embryonic stem cell (hESC) line was derived. He noted that ACT derives hESCs through a patented technique that removes a single cell from an embryo without damaging or destroying it, which eliminates many of the ethical and religious arguments against embryonic stem cell research.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory